SARS-CoV-2 Circulation in the School Setting: A Systematic Review and Meta-Analysis.

SARS-CoV-2 contract tracing infections meta-analysis schools screening students susceptibility teachers

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
28 04 2022
Historique:
received: 13 03 2022
revised: 20 04 2022
accepted: 26 04 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 18 5 2022
Statut: epublish

Résumé

The contribution of children to viral spread in schools is still debated. We conducted a systematic review and meta-analysis of studies to investigate SARS-CoV-2 transmission in the school setting. Literature searches on 15 May 2021 yielded a total of 1088 publications, including screening, contact tracing, and seroprevalence studies. MOOSE guidelines were followed, and data were analyzed using random-effects models. From screening studies involving more than 120,000 subjects, we estimated 0.31% (95% confidence interval (CI) 0.05-0.81) SARS-CoV-2 point prevalence in schools. Contact tracing studies, involving a total of 112,622 contacts of children and adults, showed that onward viral transmission was limited (2.54%, 95% CI 0.76-5.31). Young index cases were found to be 74% significantly less likely than adults to favor viral spread (odds ratio (OR) 0.26, 95% CI 0.11-0.63) and less susceptible to infection (OR 0.60; 95% CI 0.25-1.47). Lastly, from seroprevalence studies, with a total of 17,879 subjects involved, we estimated that children were 43% significantly less likely than adults to test positive for antibodies (OR 0.57, 95% CI 0.49-0.68). These findings may not applied to the Omicron phase, we further planned a randomized controlled trial to verify these results.

Identifiants

pubmed: 35564779
pii: ijerph19095384
doi: 10.3390/ijerph19095384
pmc: PMC9099553
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Pediatr Allergy Immunol. 2021 May;32(4):762-770
pubmed: 33512035
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):449-455
pubmed: 33764961
Lancet Child Adolesc Health. 2021 Apr;5(4):256-264
pubmed: 33571450
Euro Surveill. 2020 Sep;25(36):
pubmed: 32914746
Lancet Infect Dis. 2022 Jul;22(7):977-989
pubmed: 35378075
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):377-381
pubmed: 33735161
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):437-441
pubmed: 33764962
Pediatr Res. 2021 Nov;90(5):1073-1080
pubmed: 34304252
J Med Virol. 2021 Mar;93(3):1828-1831
pubmed: 33230857
J Sch Health. 2021 May;91(5):347-355
pubmed: 33768529
BMC Infect Dis. 2021 May 4;21(1):417
pubmed: 33947340
JAMA Pediatr. 2021 Jun 1;175(6):586-593
pubmed: 33480966
Clin Infect Dis. 2022 Jan 7;74(1):66-73
pubmed: 33709138
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Nat Med. 2021 Dec;27(12):2111-2119
pubmed: 34707318
Lancet. 2021 Oct 2;398(10307):1217-1229
pubmed: 34534517
Cell Rep Med. 2021 Nov 16;2(11):100452
pubmed: 34723225
J Infect. 2021 Jul;83(1):e8-e10
pubmed: 34023366
Lancet Reg Health West Pac. 2022 Feb;19:100369
pubmed: 35098182
Ital J Pediatr. 2021 Feb 2;47(1):23
pubmed: 33531046
Stat Med. 2001 Feb 28;20(4):641-54
pubmed: 11223905
Clin Infect Dis. 2021 Jul 15;73(2):e458-e465
pubmed: 32649743
J Glob Health. 2020 Dec;10(2):021104
pubmed: 33437465
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Nat Commun. 2022 Jan 27;13(1):554
pubmed: 35087051
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33574041
JAMA Netw Open. 2021 Sep 1;4(9):e2126447
pubmed: 34550382
Euro Surveill. 2020 May;25(21):
pubmed: 32489179
Int J Environ Res Public Health. 2021 Mar 08;18(5):
pubmed: 33800392
BMJ Paediatr Open. 2021 Mar 24;5(1):e001036
pubmed: 34192197
J Glob Health. 2020 Dec;10(2):021101
pubmed: 33312511
Clin Microbiol Infect. 2021 Mar;27(3):474.e1-474.e3
pubmed: 33309698
Stat Med. 2002 Jun 15;21(11):1559-73
pubmed: 12111920
BMJ. 2021 Mar 17;372:n616
pubmed: 33731327
Sci Rep. 2021 Nov 17;11(1):22373
pubmed: 34789783
CMAJ Open. 2021 Aug 24;9(3):E810-E817
pubmed: 34429325
Int J Infect Dis. 2021 Feb;103:246-256
pubmed: 33227520
Nat Commun. 2021 Feb 16;12(1):1073
pubmed: 33594076
Lancet Child Adolesc Health. 2020 Jun;4(6):421
pubmed: 32302537
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):779-784
pubmed: 34043610
J Korean Med Sci. 2020 Nov 30;35(46):e414
pubmed: 33258334
PLoS One. 2021 Sep 2;16(9):e0257046
pubmed: 34473776
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Lancet Child Adolesc Health. 2020 Nov;4(11):807-816
pubmed: 32758454
Diagnostics (Basel). 2021 Sep 29;11(10):
pubmed: 34679495
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413743
Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):
pubmed: 33827987
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):442-448
pubmed: 33764967
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
J Public Health (Oxf). 2022 Mar 7;44(1):e26-e35
pubmed: 34179987
Lancet Reg Health Eur. 2021 Jun;5:100092
pubmed: 34104904
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
JAMA. 2021 Apr 20;325(15):1561-1562
pubmed: 33605978
Clin Infect Dis. 2022 Jan 29;74(2):319-326
pubmed: 33864375
Nat Med. 2021 Dec;27(12):2078-2079
pubmed: 34824459
Lancet Infect Dis. 2021 Feb;21(2):193-202
pubmed: 33729915
BMJ Open. 2021 Jun 10;11(6):e049876
pubmed: 34112645
Euro Surveill. 2020 Dec;25(49):
pubmed: 33303065
Euro Surveill. 2021 Apr;26(15):
pubmed: 33860747
Clin Infect Dis. 2021 Nov 16;73(10):1871-1878
pubmed: 33704422
Front Psychol. 2021 Sep 16;12:746289
pubmed: 34603162
Front Pediatr. 2021 Mar 16;9:645577
pubmed: 33796490
Clin Infect Dis. 2020 Jul 28;71(15):825-832
pubmed: 32277759
Epidemiol Rev. 1987;9:1-30
pubmed: 3678409

Auteurs

Saverio Caini (S)

Institute for Cancer Research, Prevention, and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50139 Florence, Italy.

Chiara Martinoli (C)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Carlo La Vecchia (C)

Department of Clinical Sciences and Community Health, Università Degli Studi di Milano, 20133 Milan, Italy.

Sara Raimondi (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Federica Bellerba (F)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Oriana D'Ecclesiis (O)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Clementina Sasso (C)

The Italian National Institute for Astrophysics (INAF)-Osservatorio Astronomico di Capodimonte, Salita Moiariello 16, 80131 Naples, Italy.

Alessandra Basso (A)

Centre for Philosophy of Social Science (TINT), Unit of Practical Philosophy, Department of Political and Economic Studies, University of Helsinki, P.O. Box 24, 00014 Helsinki, Finland.

Giulio Cammarata (G)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Sara Gandini (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH